Enzo Biochem Reports Delaware Court Ruling

NEW YORK–(BUSINESS WIRE)– Enzo
Biochem Inc. (NYSE:ENZ) reported today that a federal judge for the
U.S. District Court for the District of Delaware has entered an order in
the actions entitled Enzo Life Sciences, Inc. v. Gen-Probe Incorporated,
Enzo Life Sciences, Inc. v. Hologic, Inc., Enzo Life Sciences, Inc. v.
Roche Molecular Systems, Inc., and Enzo Life Sciences, Inc. v. Becton,
Dickinson and Company, denying summary judgment that U.S. Patent No.
6,992,180 (“the ‘180 Patent”) is invalid for lack of written
description, but granting summary judgment that the ‘180 Patent is
invalid for lack of enablement.

The ruling addresses only one patent at issue in the ongoing patent
infringement actions between Enzo and the defendants in each case. At
least one other Enzo patent remains pending against each defendant in
those or parallel actions. Enzo believes that the Court’s ruling was in
error, and is exploring options for review of the decision.

About
Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and intellectual
property through the development of unique diagnostic platform
technologies that provide numerous advantages over previous standards. A
global company, Enzo Biochem utilizes cross-functional teams to develop
and deploy products, systems and services that meet the ever-changing
and rapidly growing needs of health care today and into the future.
Underpinning Enzo Biochem’s products and technologies is a broad and
deep intellectual property portfolio, with patent coverage across a
number of key enabling technologies.

Except for historical information, the matters discussed in this news
release may be considered « forward-looking » statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management, including those related
to cash flow, gross margins, revenues, and expenses which are dependent
on a number of factors outside of the control of the Company including,
inter alia, the markets for the Company’s products and services, costs
of goods and services, other expenses, government regulations,
litigation, and general business conditions. See Risk Factors in the
Company’s Form 10-K for the fiscal year ended July 31, 2016. Investors
are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The Company
disclaims any obligations to update any forward-looking statement as a
result of developments occurring after the date of this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170629005369/en/